Jakub Kancerek

Mr. Jakub Kancerek

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JKJakub Kancerek
Jakub Kancerek
ŁZŁukasz Zniszczoł
Łukasz Zniszczoł
PLPiotr Lewandowski
Piotr Lewandowski
RWRomuald Wojnicz
Romuald Wojnicz
Amyloidosis is a group of disorders caused by extracellular deposition of insoluble fibrillar proteins, leading to progressive organ dysfunction. Cardiac amyloidosis is clinically significant, as myocardial infiltration results in restrictive cardiomyopathy, arrhythmias, and heart failure. The main subtypes are light-chain (AL) and transthyretin (ATTR) amyloidosis, while AA and isolated atrial amyloidosis (IAA) are less common. Accurate subtype identification is crucial for management and prognosis. Diagnosis requires a multimodal approach combining imaging and tissue-based techniques. Echocardiography is usually first-line, showing increased wall thickness, biatrial enlargement, and apical sparing. Cardiac magnetic resonance (CMR) provides superior tissue characterization through late gadolinium enhancement and elevated extracellular volume. Nuclear scintigraphy with 99mTc-labeled tracers enables non-invasive ATTR detection, while amyloid-specific PET tracers show potential for early diagnosis. Histochemical confirmation remains essential. Congo Red staining with apple-green birefringence under polarized light is the diagnostic gold standard, supported by Thioflavin T, PAS, and Alcian Blue stains. Immunohistochemistry and mass spectrometry aid amyloid typing, while electron microscopy provides ultrastructural confirmation. Integrating imaging, histochemical, immunohistochemical, and proteomic techniques enhances early recognition and precise classification, improving therapeutic strategies and patient outcomes.

7 February 2025 in BMJ Open
Verified
Journal Article
Open access
PLPiotr Lewandowski
Piotr Lewandowski
MBMaciej Baron
Maciej Baron
MRMarcin Rojek
Marcin Rojek
MGMarcin Goławski
Marcin Goławski
KKKarol Krystek
Karol Krystek
RWRomuald Wojnicz
Romuald Wojnicz
Introduction: Myocarditis is an inflammatory heart disease resulting from infections, toxic exposures or autoimmune reactions. Irrespective of the factors responsible for this disease, cytokines play an important role in regulating the immunological response involved in its development and progression. Accordingly, this protocol aims to conduct a systematic review and meta-analysis summarising previous research on serum and plasma levels of cytokines in patients with myocarditis and inflammatory dilated cardiomyopathy. Methods and analysis: Four scientific databases: PubMed, Embase, Scopus and Web of Science, will be searched. The estimated date of the search will be 30 March 2024. Each stage of the review, including the study selection, data extraction, risk of bias and quality of evidence assessments, will be performed in duplicate. Studies meeting the following criteria will be eligible for inclusion: (1) studies involving ‘myocarditis’ or ‘inflammatory dilated cardiomyopathy’ and (2) studies are required to report serum levels of any cytokine. Meta-analyses will be used to summarise serum levels of each cytokine if possible. Subgroup analysis will be stratified by age, sex, sample size, New York Heart Association scale, cardiac Troponin T, N-terminal prohormone of brain natriuretic peptide, C reactive protein, number of lymphocytes per mm 2 in the endomyocardial biopsy. Ethics approval and dissemination: This study does not require ethics approval. After completion, the results will be published in a peer-reviewed paper. Data generated during the study will be published in an open access repository. PROSPERO registration number: CRD42024519625

29 September 2026 in Coronary Artery Disease
Verified
Journal Article
Open access
JKJakub Kancerek
Jakub Kancerek
ASAlexander Suchodolski
Alexander Suchodolski
RWRomuald Wojnicz
Romuald Wojnicz
MSMariola Szulik
Mariola Szulik
KMKarol Miszalski-Jamka
Karol Miszalski-Jamka
JGJan Głowacki
Jan Głowacki
Cardiac amyloidosis has emerged as an important and underrecognized cause of heart failure with preserved ejection fraction, particularly in elderly patients who commonly carry concomitant coronary artery disease. The coexistence of these two conditions creates a layered diagnostic and therapeutic problem. Epicardial atherosclerosis is present in roughly 30–40% of patients with cardiac amyloidosis, yet the dominant ischemic mechanism in the amyloidotic heart is rarely flow-limiting epicardial obstruction. Instead, ischemia is driven by coronary microvascular dysfunction arising from amyloid infiltration of the arteriolar wall, capillary rarefaction, extravascular compression by the hypertrophied myocardium, and in light-chain disease direct endothelial toxicity. This distinction has immediate clinical consequences. Chronic troponin elevation from subendocardial ischemia and wall stress frequently mimics acute coronary syndromes, prompting invasive procedures that carry disproportionate risk in this population, while pressure-derived indices such as fractional flow reserve are unreliable because the infiltrated microvasculature cannot mount a normal hyperemic response. This review synthesizes the pathophysiological interplay between amyloid infiltration and coronary disease, defines the diagnostic pitfalls of the dual pathology, and proposes a multimodality imaging strategy, integrating advanced echocardiography, cardiac magnetic resonance, nuclear perfusion imaging, and cardiac computed tomography that distinguishes microvascular from epicardial ischemia and supports more rational clinical decisions. Critical evidence gaps, foremost the absence of randomized data comparing revascularization with medical therapy in this population, are discussed alongside emerging tools for refining ischemic assessment in the amyloidotic heart.

Verified
Journal Article
Open access
PDF file
JKJakub Kancerek
Jakub Kancerek
Damian ŚwierczekDamian Świerczek
Damian Świerczek
WBWiktoria Baron
Wiktoria Baron
MRMarcin Rojek
Marcin Rojek
PLPiotr Lewandowski
Piotr Lewandowski
RWRomuald Wojnicz
Romuald Wojnicz
Cardiac sarcoidosis (CS) is a critical and frequently underdiagnosed phenotype of sarcoidosis, characterized by non-caseating granulomatous infiltration of the myocardium. This review synthesizes current knowledge regarding the pathogenesis, diagnosis, and management of CS. The disease manifests with a heterogeneous clinical spectrum ranging from asymptomatic conduction abnormalities to life-threatening ventricular arrhythmias and heart failure. Diagnosis remains challenging due to the patchy distribution of granulomas, which limits the sensitivity of endomyocardial biopsy. Consequently, a multimodal diagnostic approach is essential, integrating advanced imaging modalities such as cardiac magnetic resonance (CMR) with late gadolinium enhancement (LGE) and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). These tools not only facilitate detection but also enable the differentiation of active inflammation from chronic fibrosis. Histopathological assessment, supported by specific immunophenotyping and electron microscopy, remains the gold standard for confirming diagnosis and excluding mimics like giant cell myocarditis or infectious granulomatous diseases. Management requires a multidisciplinary strategy combining immunosuppressive therapy, primarily corticosteroids and steroid-sparing agents, with guideline-directed cardiac care, including implantable cardioverter-defibrillators for arrhythmia risk stratification. Emerging biomarkers and artificial intelligence-driven imaging analysis promise to further refine risk stratification and therapeutic monitoring, advancing precision medicine in this complex disorder.

Verified
Journal Article
Open access
PDF file
Damian ŚwierczekDamian Świerczek
Damian Świerczek
MDMaja Anna Dreger
Maja Anna Dreger
JJJakub Jatkowski
Jakub Jatkowski
JKJakub Kancerek
Jakub Kancerek
BDBogna Drozdzowska
Bogna Drozdzowska
RWRomuald Wojnicz
Romuald Wojnicz
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has become one of the most common chronic liver diseases worldwide, representing a major global health challenge closely linked to metabolic syndrome, obesity, and type 2 diabetes mellitus (TD2M). The condition is characterized by a multisystem nature driven by complex multifactorial mechanisms, including insulin resistance, lipotoxicity, mitochondrial dysfunction, genetic predispositions, and gut-liver axis alterations. Although liver biopsy remains the gold standard, non-invasive markers and advanced imaging methods are of key importance for early risk stratification. Furthermore, while liver-related complications such as fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) are significant, cardiovascular disease remains the leading cause of mortality in patients with MASLD. Current management relies primarily on lifestyle modifications, targeted pharmacotherapy (such as pioglitazone, GLP-1 receptor agonists, SGLT-2 inhibitors), and novel experimental therapies. Consequently, MASLD requires a multidisciplinary approach emphasizing early diagnosis, risk stratification, and comprehensive treatment of both hepatic and extrahepatic manifestations.